Previous 10 | Next 10 |
Liminal BioSciences (NASDAQ:LMNL): Q3 Net loss from continuing operations, net of taxes was $9.7M Cash balance of $116.7M Press Release For further details see: Liminal BioSciences reports Q3 results
Liminal BioSciences Reports Third Quarter 2021 Financial Results Canada NewsWire Closing of the Sale of a Rare Pediatric Disease Priority Review Vou cher for gross proceeds of USD105M Closing of the Sale of the Remaining Plasma-Derived Therapeuti...
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business PR Newswire LAVAL, QC and CAMBRIDGE, England , Oct. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), ...
Liminal BioSciences Announces Closing of Sale of Priority Review Voucher PR Newswire LAVAL, QC and CAMBRIDGE, England , Sept. 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that i...
Liminal BioSciences Inc. (LMNL) Q2 2021 Earnings Conference Call August 17, 2021 08:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Patrick Sartore - President Murielle Lortie - Chief Financial Officer C...
The following slide deck was published by Liminal BioSciences Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Liminal BioSciences Inc. 2021 Q2 - Results - Earnings Call Presentation
Liminal BioSciences Reports Second Quarter 2021 Financial Results Canada NewsWire Receipt of FDA Approval for Ryplazim ® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Pl...
Gainers: LMNL +15.0%. SONO +10.6%. HUT +8.2%. EBON +4.5%. CAN +4.0%. Losers: JRJC -13.8%. WDC -6.1%. SDGR -5.6%. OGI -4.5%. ISEE -2.7%. For further details see: LMNL, SONO, JRJC and WDC among after hours movers
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +84%, Allied Healthcare Products (NASDAQ:AHPI) +39%, IMV (NASDAQ:IMV) +29%, Exagen (NASDAQ:XGN) +26%, Myomo (NYSE:MYO) +22%. Losers: SmileDirectClub (NASDAQ:SDC) -23%, EyeGate Pharmaceutica...
Liminal BioSciences (NASDAQ: LMNL) is one of the best-performing stocks on the public market today. If you want to invest in Liminal BioSciences, or if you simply want to find out more about the company and why it is surging in value, this article should answer all of your q...
News, Short Squeeze, Breakout and More Instantly...
Liminal Biosciences Inc Company Name:
LMNL Stock Symbol:
NASDAQ Market:
Liminal Biosciences Inc Website:
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Liminal BioSciences Inc. (LMNL) is expected to report for Q3 2023
LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Sept. 26, 2023 /CNW/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce tha...